136 related articles for article (PubMed ID: 17123638)
1. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice.
Hostetler KY; Beadle JR; Trahan J; Aldern KA; Owens G; Schriewer J; Melman L; Buller RM
Antiviral Res; 2007 Mar; 73(3):212-8. PubMed ID: 17123638
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
Ruiz J; Beadle JR; Buller RM; Schreiwer J; Prichard MN; Keith KA; Lewis KC; Hostetler KY
Bioorg Med Chem; 2011 May; 19(9):2950-8. PubMed ID: 21493074
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Buller RM; Owens G; Schriewer J; Melman L; Beadle JR; Hostetler KY
Virology; 2004 Jan; 318(2):474-81. PubMed ID: 14972516
[TBL] [Abstract][Full Text] [Related]
4. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
5. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.
Aldern KA; Ciesla SL; Winegarden KL; Hostetler KY
Mol Pharmacol; 2003 Mar; 63(3):678-81. PubMed ID: 12606777
[TBL] [Abstract][Full Text] [Related]
6. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
[TBL] [Abstract][Full Text] [Related]
7. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
Antiviral Res; 2008 Jan; 77(1):39-49. PubMed ID: 17904231
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.
Ruiz JC; Beadle JR; Aldern KA; Keith KA; Hartline CB; Kern ER; Hostetler KY
Antiviral Res; 2007 Jul; 75(1):87-90. PubMed ID: 17367874
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.
Robbins SJ; Jackson RJ; Fenner F; Beaton S; Medveczky J; Ramshaw IA; Ramsay AJ
Antiviral Res; 2005 Apr; 66(1):1-7. PubMed ID: 15781125
[TBL] [Abstract][Full Text] [Related]
11. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
Kern ER; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Quenelle DC
Antimicrob Agents Chemother; 2004 Sep; 48(9):3516-22. PubMed ID: 15328119
[TBL] [Abstract][Full Text] [Related]
12. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
Ciesla SL; Trahan J; Wan WB; Beadle JR; Aldern KA; Painter GR; Hostetler KY
Antiviral Res; 2003 Aug; 59(3):163-71. PubMed ID: 12927306
[TBL] [Abstract][Full Text] [Related]
13. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.
Wan WB; Beadle JR; Hartline C; Kern ER; Ciesla SL; Valiaeva N; Hostetler KY
Antimicrob Agents Chemother; 2005 Feb; 49(2):656-62. PubMed ID: 15673748
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
16. Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.
Wang H; Chhablani J; Freeman WR; Beadle JR; Hostetler KY; Hartmann K; Conner L; Aldern KA; Pearson L; Cheng L
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9391-6. PubMed ID: 22058340
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.
Hostetler KY
Viruses; 2010 Oct; 2(10):2213-2225. PubMed ID: 21994617
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
20. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
